Neurocrine Biosciences

NBIXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$14.460 B

$142.25 -1.19%

Close of 22 Sept 2026

Revenue

$2.86B

#952 by revenue

Earnings

$478.6M

#630 by earnings

Shares outstanding

101,649,181

Latest filing cover page

P/E ratio

30.2

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#6BiogenBIIB$33.3B
#7BioNTech SEBNTX$25.3B
#8Neurocrine BiosciencesNBIX$14.5B
#9ExelixisEXEL$14.4B
#10Halozyme TherapeuticsHALO$13.1B

What if Neurocrine Biosciences were worth as much as…

Open the what-if tool →

Gold $30.2T

$297,434.46

Per share 2,091× higher

Bitcoin $1.74T

$17,133.98

Per share 120× higher

Nvidia $5.52T

$54,262.78

Per share 381× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Neurocrine Biosciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.